Oxford Biomedica Plc Cash flow Statement
Figures in Million
Consolidated Cash Flow Results
Dec'25
Dec'24
Dec'23
Dec'22
Dec'21
Dec'20
No of Months
12
12
12
12
12
12
Profit Before Tax
-31.00
-47.00
-188.00
-45.00
19.00
-6.00
Adjustment
0.00
0.00
0.00
0.00
0.00
0.00
Changes In working Capital
3.00
-34.00
17.00
4.00
-12.00
-12.00
Cash Flow after changes in Working Capital
0.00
0.00
0.00
0.00
0.00
0.00
Cash Flow from Operating Activities
-1.00
-50.00
-28.00
-16.00
24.00
3.00
Cash Flow from Investing Activities
-8.00
1.00
-1.00
-56.00
-9.00
-10.00
Cash Flow from Financing Activities
46.00
6.00
-8.00
103.00
47.00
38.00
Net Cash Inflow / Outflow
36.00
-43.00
-37.00
32.00
62.00
30.00
Opening Cash & Cash Equivalents
0.00
0.00
0.00
0.00
0.00
0.00
Cash & Cash Equivalent on Amalgamation / Take over / Merger
0.00
0.00
0.00
0.00
0.00
0.00
Cash & Cash Equivalent of Subsidiaries under liquidations
0.00
0.00
0.00
0.00
0.00
0.00
Translation adjustment on reserves / op cash balances foreign subsidiaries
0.00
0.00
0.00
0.00
0.00
0.00
Effect of Foreign Exchange Fluctuations
0.00
0.00
0.00
2.00
0.00
0.00
Closing Cash & Cash Equivalent
0.00
0.00
0.00
0.00
0.00
0.00
Figures in GBP Million
Seasonal companies are compared with the same quarter last year
Seasonal companies are compared with the same quarter last year
Compare Cash Flow Results of Oxford Biomedica Plc
Figures in Million
consolidated Cash Flow Results
Change(GBP)
Change(%)
Profit Before Tax
-31.936
-70.5658147422046
39.00
54.74%
Adjustment
0
0
0.00
0.00%
Changes In working Capital
3.23
-2.36969654659138
5.00
236.30%
Cash Flow after changes in Working Capital
0
0
0.00
0.00%
Cash Flow from Operating Activities
-1.701
-64.5964254588122
63.00
97.37%
Cash Flow from Investing Activities
-8.098
48.0222078260247
-56.00
-116.86%
Cash Flow from Financing Activities
46.843
-4.80161375178682
50.00
1075.57%
Net Cash Inflow / Outflow
36.234
-21.3758313845743
57.00
269.51%
Opening Cash & Cash Equivalents
0
0
0.00
0.00%
Cash & Cash Equivalent on Amalgamation / Take over / Merger
0
0
0.00
0.00%
Cash & Cash Equivalent of Subsidiaries under liquidations
0
0
0.00
0.00%
Translation adjustment on reserves / op cash balances foreign subsidiaries
0
0
0.00
0.00%
Effect of Foreign Exchange Fluctuations
-0.81
0
0.00
0.00%
Closing Cash & Cash Equivalent
0
0
0.00
0.00%
Cash Flow - Snapshot (Consolidated) - Dec'25
YoY Growth in year ended Dec 2025 is 96.64% vs -78.24% in Dec 2024
Dec'25
Dec'24
Change(%)
Cash Flow from Operating Activities
-1.70
-50.63
96.64%






